Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
暂无分享，去创建一个
H. Goldschmidt | Shaji K. Kumar | T. Plesner | R. Orlowski | H. Nahi | N. Raje | P. Moreau | M. Macro | X. Leleu | S. Basu | L. Frenzel | T. Facon | J. Vermeulen | S. Usmani | M. O'Dwyer | A. Perrot | M. Tiab | C. Hulin | K. Weisel | N. Bahlis | T. Ahmadi | Jianping Wang | C. Uhlar | J. Mace | C. Venner | H. Quach | B. Tromp | M. Delioukina | R. Van Rampelbergh